Netherlands – Sublingual allergy therapy gets another boost as Fornix BioSciences N.V release results on Oralgen Grass Pollen sublingual drops. New research shows that a longer treatment period yields improved symptom control.

Last year, Fornix BioSciences reported on a major clinical study into the effectiveness and safety of Oralgen Grass Pollen for a single season. Treatment for a single grass pollen season showed promising results as well as definite benefits to sublingual treatment.

Test subjects from the first season of treatment were requested to continue for a second year of treatment. The follow up study looked at 356 individuals who were willing to continue with the research.

After the second season on Oralgen Grass Pollen, the group with the highest dosage saw a 47% decrease in allergic symptoms in relation to the placebo group. This was a substantial increase over the results for the same dosage group after just one season of treatment. After one season, the same group had reported a 27% drop in symptoms.

As with the first study, the follow up study showed that the treatment was safe and well tolerated by patients. Side effects were shown to drop from the first season to the second. No serious side effects were found.

Oralgen Grass Pollen treatment is still in the process of getting approval for use in the European market. It is just one of the products which Fornix is seeking to take to the public. Fornix also has sublingual treatments for dust mite allergy and tree pollen allergy.

Fornix CEO Cees Bergman said: “The results encourage us in our efforts and our decision to make substantial investments to ensure that our products receive registration.” Unfortunately, because the product is not yet registered for patient use, the public will have to wait some time longer for this product (and its companion products) to be available.

Source: PipelineReview.com